Vocabria FDA Approval History
Last updated by Judith Stewart, BPharm on March 4, 2021.Vocabria (cabotegravir) is a human immunodeficiency virus type-1 (HIV-1) integrase strand transfer inhibitor (INSTI) indicated in combination with Edurant (rilpivirine) for short-term treatment of HIV-1 infection in adults who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine, for use as:
- oral lead-in to assess the tolerability of cabotegravir prior to administration of Cabenuva (cabotegravir; rilpivirine) extended-release injectable suspensions.
- oral therapy for patients who will miss planned injection dosing with Cabenuva.
Development timeline for Vocabria
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.